Global biopharmaceutical company
Appears in 8 stories
Developing admilparant, a potential first-in-class LPA1 receptor antagonist for IPF
Bristol Myers Squibb's experimental lung disease drug admilparant met its main goal in a late-stage trial, but only at the lower of two tested doses. The 60 milligram dose significantly slowed the decline in lung function among patients with idiopathic pulmonary fibrosis, while the 120 milligram dose missed the statistical threshold.
Updated 2 hours ago
Paused autoimmune CAR-T trials over reversible inflammatory events
Novartis paused its autoimmune CAR-T trials this month after three patients died from a severe immune reaction, and Bristol Myers paused its own over similar inflammatory events. The same week, Kyverna Therapeutics released 12 months of follow-up data on miv-cel, its rival therapy, reporting sustained improvement in stiff person syndrome patients with no high-grade immune toxicity.
Updated Sep 24
Anchor tenant at Campus Point
A venue called The Alexandria at 4150 Campus Point Court in San Diego applied for a California liquor license. The application appeared on the state's ABC licensing list on September 18, 2026.
Updated Sep 18
Licensor of five immunology programs to Beeline; equity investor
Beeline Medicines' afimetoran, a once-daily oral pill for lupus, met its primary endpoint in a Phase 2 trial. The result moves the biotech into Phase 3 (pivotal) development for two forms of the disease.
Updated Sep 9
Maker of competing oral psoriasis drug Sotyktu, which ICOTYDE outperformed in head-to-head trials
For two decades, treating moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions many patients refused or abandoned. On March 18, 2026, the FDA approved ICOTYDE, a once-daily pill that blocks the IL-23 receptor like injectable biologics. In trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of placebo.
Updated May 30
Awaiting FDA decision on Sotyktu expansion into psoriatic arthritis
For most of the past decade, people with psoriatic arthritis who wanted a pill had one real choice: Janus kinase (JAK) inhibitors. The FDA slapped those drugs with its strongest safety warning in 2021, after a major trial linked them to higher rates of heart attacks, blood clots, cancer, and death.
Building real-world evidence for Cobenfy; planning UK launch in 2026
The FDA approved Cobenfy for schizophrenia in September 2024—the first drug to treat the condition through muscarinic receptors rather than dopamine, a different approach than any approved in the previous 50 years. Bysanti (milsaperidone) followed in February 2026, cleared for both schizophrenia and bipolar I disorder. For the roughly 7 million Americans with these conditions, the treatment menu is wider than it was two years ago.
Updated May 29
Incumbent oral TYK2 competitor via Sotyktu; a key benchmark for Takeda
Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).
Updated May 15
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
